Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Adult
Aged
Anemia
/ chemically induced
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Boron Compounds
/ adverse effects
Cohort Studies
Dexamethasone
/ adverse effects
Female
Glycine
/ adverse effects
Humans
Kaplan-Meier Estimate
Lenalidomide
/ adverse effects
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Neoplasm Recurrence, Local
/ drug therapy
Neutropenia
/ chemically induced
Slovakia
/ epidemiology
Effectiveness
Ixazomib
Multiple myeloma
Real-world data
Relapsed/refractory
Safety
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
21
06
2021
accepted:
08
09
2021
pubmed:
23
9
2021
medline:
14
1
2022
entrez:
22
9
2021
Statut:
ppublish
Résumé
Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy. Registration study "TOURMALINE MM-1" was published in 2016. Nevertheless, clinical trials are significantly different from real-world use. From June 2016 to December 2018, IRd was available for Slovak patients with relapsed/refractory MM through a Named Patient Program. The aim of this study was to evaluate the efficacy and safety of ixazomib. We analyzed in this cohort study outcomes of 106 MM patients treated with IRd at 2 academic centers. The median age at diagnosis was 63 years (44-78). The median number of prior lines was 2 (1-7). The majority had high international staging system (ISS) score: 18, 29, and 59 were in the ISS I, ISS II, and ISS III groups, respectively. Treatment continued until progression, unacceptable toxicity, or death. The median follow-up for the entire cohort was 29 (0-49) months. The overall response rate was 74.5% (complete remission, 7.5%; partial remission, 67%). The median overall survival was not reached. Median progression-free survival (PFS) was 43 months (95% CI 35.6-50.4). The Kaplan-Meier method was used to generate survival curves, and we compared the influence of different factors on PFS. The most common hematological adverse events of any grade were neutropenia (90.4%), anemia (55.6%), and thrombocytopenia (43.4%). Our real-world data support the use of IRd as a highly effective and well-tolerated oral treatment protocol for relapsed myeloma.
Identifiants
pubmed: 34550463
doi: 10.1007/s00277-021-04663-0
pii: 10.1007/s00277-021-04663-0
doi:
Substances chimiques
Boron Compounds
0
ixazomib
71050168A2
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Glycine
TE7660XO1C
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-89Subventions
Organisme : vedecká grantová agentúra mšvvaš sr a sav
ID : VEGA 1/0187/17
Organisme : agentúra na podporu výskumu a vývoja
ID : APVV-17-0054
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Parrondo RD, Alegria V, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S (2021) Ixazomib and lenalidomide maintenance therapy in multiple myeloma. Ann Hematol 100(3):851–853. https://doi.org/10.1007/s00277-020-04340-8
doi: 10.1007/s00277-020-04340-8
pubmed: 33161454
Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, Zhang W, Yang W, Li B, Fu C, Chen B, Hua L, Wang L, Luo J, Yang Y, Xu T, Wang W, Huang Y, Wu G, Liu P (2020) Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol 99(11):2589–2598. https://doi.org/10.1007/s00277-020-04234-9
doi: 10.1007/s00277-020-04234-9
pubmed: 32892275
pmcid: 7474576
Röllig C, Knop S, Bornhäuser M (2015) Multiple myeloma. Lancet 385(9983):2197–208. https://doi.org/10.1016/S0140-6736(14)60493-1
doi: 10.1016/S0140-6736(14)60493-1
pubmed: 25540889
Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S (2019) Role of proteasome inhibitors in relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 19(1):9–22. https://doi.org/10.1016/j.clml.2018.08.016
doi: 10.1016/j.clml.2018.08.016
pubmed: 30287200
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–34. https://doi.org/10.1056/NEJMoa1516282
doi: 10.1056/NEJMoa1516282
pubmed: 27119237
Mansournia MA, Higgins JP, Sterne JA, Hernán MA (2017) Biases in randomized trials: a conversation between trialists and epidemiologists. Epidemiology 28(1):54–59. https://doi.org/10.1097/EDE.0000000000000564
doi: 10.1097/EDE.0000000000000564
pubmed: 27748683
pmcid: 5130591
Ramagopalan SV, Simpson A, Sammon C (2020) Can real-world data really replace randomised clinical trials? BMC Med 18(1):13. https://doi.org/10.1186/s12916-019-1481-8
doi: 10.1186/s12916-019-1481-8
pubmed: 31937304
pmcid: 6961357
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5
doi: 10.1016/S1470-2045(14)70442-5
pubmed: 25439696
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420. https://doi.org/10.1200/JCO.2005.04.242
doi: 10.1200/JCO.2005.04.242
pubmed: 15809451
Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60 . Accessed June 21, 2021
Smolewski P, Rydygier D (2019) Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opin Investig Drugs 28(5):421–433. https://doi.org/10.1080/13543784.2019.1596258
doi: 10.1080/13543784.2019.1596258
pubmed: 30907163
Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK (2016) Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Des Devel Ther 10:217–226. https://doi.org/10.2147/DDDT.S93602
doi: 10.2147/DDDT.S93602
pubmed: 26811670
pmcid: 4714737
Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970–1980. https://doi.org/10.1158/0008-5472.CAN-09-2766
doi: 10.1158/0008-5472.CAN-09-2766
pubmed: 20160034